Clinical trials: Schizophrenia, Undifferentiated
Paranoid Schizophrenia, Schizophrenia
MK0557 for the Treatment of Cognitive Impairment in Patients With Schizophrenia (0557-027)
The purpose of this study is to determine the safety and effectiveness of an investigational drug for the treatment of cognitive impairment in patients with schizophrenia.
- Trial name
- NCT00482430
- Testing
- MK0557
- Volunteers
- 50 people
- Sponsor
- Merck Sharp & Dohme LLC
Schizophrenia
Study Of Talnetant Versus Placebo And Risperidone In Schizophrenia
This study will evaluate whether talnetant (200mg, 400mg, 600mg) twice a day is effective compared to placebo and risperidone 1-3mg twice a day in treating the positive and negative symptoms of schizophrenia.
- Trial name
- NCT00103727
- Testing
- Talnetant, risperidone
- Where
- 22 sites in United States
- Volunteers
- 282 people
- Sponsor
- GlaxoSmithKline
Schizophrenia, Paranoid, Schizophrenia, Disorganized
Flexible Dose, Long-term Safety Study of Asenapine for the Treatment of Schizophrenia in Adolescents (P05897)
This study is designed to evaluate whether asenapine, which is approved by the United States Food and Drug Administration (US FDA) for acute treatment of schizophrenia in adults, is generally safe and well tolerated in…
- Conditions
- Schizophrenia, Paranoid, Schizophrenia, Disorganized, Schizophrenia, Undifferentiated
- Trial name
- NCT01190267
- Testing
- asenapine
- Volunteers
- 204 people
- Sponsor
- Organon and Co
Schizophrenia
Transcutaneous Non-invasive Vagus Nerve Stimulation (t-VNS) in the Treatment of Schizophrenia
Randomized, controlled, double-blind, two-armed clinical investigation to show the efficacy and safety of transcutaneous vagus nerve stimulation (t-VNS), applied at the left auricle, in schizophrenia.
- Trial name
- 02VNS2009 (NCT01176721)
- Testing
- t-VNS verum
- Where
- 2 sites in Germany
- Volunteers
- 20 people
- Sponsor
- cerbomed GmbH
Schizophrenia, Undifferentiated Type
Comparison of the Effects of Aripiprazole and Risperidone on the Pattern of Brain Activation in Schizophrenic Patients
After an initial screening visit, including an assessment of psychiatric disorders, patients stabilized on antipsychotic medication (aripiprazole or risperidone) for at least 6 weeks and control subjects will undergo an…
- Trial name
- NCT01109147
- Testing
- Imagery, pharmacogenetic sampling
- Where
- 2 sites in France
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Qualissima
Schizophrenia, Catatonic, Schizophrenia, Disorganized
Evaluation of Efficacy and Safety of Long-acting Risperidone Microspheres in Patients With Schizophrenia or Other Psychotic Disorders When Switching From Typical Antipsychotic (Oral/Depot) or Atypical Oral Other Than Risperidone
The purpose of this study is to evaluate the efficacy, tolerability and safety of patients on long-acting Risperidone microshpheres injection.
- Conditions
- Schizophrenia, Catatonic, Schizophrenia, Disorganized, Schizophrenia, Paranoid, Schizophrenia
- Trial name
- NCT00563017
- Testing
- Long-acting Risperidone microspheres injection
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Hospital Authority, Hong Kong
Schizophrenia, Paranoid, Schizophrenia, Disorganized
Fixed Dose Efficacy and Safety Study of Asenapine for the Treatment of Schizophrenia in Adolescents (P05896)
This study is designed to evaluate whether asenapine, which is approved by the United States Food and Drug Administration (US FDA) for acute treatment of schizophrenia in adults, is also effective in adolescents with…
- Conditions
- Schizophrenia, Paranoid, Schizophrenia, Disorganized, Schizophrenia, Undifferentiated
- Trial name
- NCT01190254
- Testing
- asenapine 2.5 mg, asenapine 5.0 mg
- Volunteers
- 306 people
- Sponsor
- Organon and Co
Schizophrenia, Undifferentiated, Anorexia
Representations and Strategies for Recovery
In the recent context of deinstitutionalization and longitudinal studies pointing to a large number of positive long-term outcommes for people affected by a psychiatric disorder (schizophrenia, bipolar disorder, eating disorder…
- Conditions
- Schizophrenia, Undifferentiated, Anorexia, Bipolar Disorders, Personality Disorders
- Trial name
- EPR (NCT03028545)
- Testing
- Collection of the individual narrative, semi-directed interviews
- Where
- France
- Volunteers
- 37 people
- Sponsor
- Hôpital le Vinatier
Paranoid Schizophrenia
MK0249 for the Treatment of Cognitive Impairment in Patients With Schizophrenia (0249-016)
The purpose of this study is to determine the safety and effectiveness of an investigational drug MK0249 for the treatment of the cognitive impairment in patients with schizophrenia.
- Trial name
- NCT00506077
- Testing
- MK0249
- Volunteers
- 55 people
- Sponsor
- Merck Sharp & Dohme LLC